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Abstract
Cyclooxygenases (COX) are prostanoid synthesizing enzymes constitutively expressed in the brain that contribute to
excitotoxic neuronal cell death. While the neurotoxic role of COX-2 is well established and has been linked to prostaglandin
E2 synthesis, the role of COX-1 is not clearly understood. In a model of N-Methyl-D-aspartic acid (NMDA) induced
excitotoxicity in the mouse cerebral cortex we found a distinctive temporal profile of COX-1 and COX-2 activation where
COX-1, located in microglia, is responsible for the early phase of prostaglandin E2 synthesis (10 minutes after NMDA), while
both COX-1 and COX-2 contribute to the second phase (3–24 hours after NMDA). Microglial COX-1 is strongly activated by
ATP but not excitatory neurotransmitters or the Toll-like receptor 4 ligand bacterial lipopolysaccharide. ATP induced
microglial COX-1 dependent prostaglandin E2 synthesis is dependent on P2X7 receptors, extracellular Ca
2+ and cytoplasmic
phospholipase A2. NMDA receptor activation induces ATP release from cultured neurons leading to microglial P2X7
receptor activation and COX-1 dependent prostaglandin E2 synthesis in mixed microglial-neuronal cultures. Pharmaco-
logical inhibition of COX-1 has no effect on the cortical lesion produced by NMDA, but counteracts the neuroprotection
exerted by inhibition of COX-2 or observed in mice lacking the prostaglandin E2 receptor type 1. Similarly, the
neuroprotection exerted by the prostaglandin E2 receptor type 2 agonist butaprost is not observed after COX-1 inhibition.
P2X7 receptors contribute to NMDA induced prostaglandin E2 production in vivo and blockage of P2X7 receptors reverses
the neuroprotection offered by COX-2 inhibition. These findings suggest that purinergic signaling in microglia triggered by
neuronal ATP modulates excitotoxic cortical lesion by regulating COX-1 dependent prostanoid production and unveil a
previously unrecognized protective role of microglial COX-1 in excitotoxic brain injury.
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Introduction
Cyclooxygenases, enzymes that synthesize prostanoids (i.e. pros-
taglandins, thromboxanes and prostacyclines) from arachidonic acid,
have been implicated in the mechanisms of a wide variety of
pathological conditions, including several brain diseases [1]. Two
genetically distinct isoforms of COX have been identified: COX-1
and COX-2. While COX-1 contributes to the production of
prostanoids involved in normal cellular functions and enzyme levels
are generallystableincellsthatexpressthisisozyme,COX-2is highly
inducible at the transcriptional level and is upregulated in different
organs in pathological states associated with inflammation [2,3].
In brain, COX-2 is constitutively expressed in neurons [4] and
has been implicated in the development of brain lesions in models
of excitotoxicity, hypoxia-ischemia, trauma, neurodegeneration
and neuroinflammation [5]. The neurotoxic effect of COX-2 is
mediated by prostaglandin (PG) E2 via activation of the PGE2
receptor subtype 1 (EP1) on neurons [6,7]. PGE2 can also induce
neuroprotection by activating neuronal EP2 receptors [8].
However, in models of inflammation or Aß neurotoxicity
microglial EP2 receptor activation is deleterious, an effect
mediated by the release of cytotoxic factors from microglia [9].
Thus, PGE2 may have beneficial or deleterious effects depending
on its cellular source, the type of EP receptor expressed in target
cells, and the cell type expressing EP receptors.
The role of COX-1 in neurotoxicity is far less clear. Although it
has been suggested that both COX-1 and COX-2 contribute to
NMDA-induced PGE2 production and free radical damage in
hippocampus [10], COX-1 is not involved in excitotoxic cell death
in a model of NMDA neurotoxicity in the cortex [11]. Similarly,
both COX-1 and COX-2 have been reported to contribute to
hippocampal damage after global cerebral ischemia [12], but
COX-1 is protective in a model of focal cerebral ischemia [11].
These conflicting observations indicate that the role of COX-1 is
complex and may depend on the cell type expressing COX-1 and
on the context in which the injury is produced.
Therefore, in the present study we addressed the relative
contribution of COX-1 and COX-2 to the PGE2 production and
brain damage produced by cortical injection of NMDA. We found
that COX-1, expressed mainly in microglia, is a major source of
PGE2 in the early stages of NMDA neurotoxicity. Although COX-
1 does not directly contribute to the injury, COX-1 enzymatic
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inhibition, EP1 receptor deletion or EP2 receptor activation.
Furthermore we find that microglial COX-1 is activated through
purinergic signaling initiated by neuronal ATP release, leading to
activation of P2X7 receptors and Ca
2+-dependent phospholipase
A2. The findings unveil a previously unrecognized neuroprotective
role of purinergic signaling and microglial COX-1 in excitotoxic
brain injury.
Methods
Reagents
NMDA, MK-801, ATP, periodate-oxidized ATP (oxATP),
29(39)-O-(4-Benzoylbenzoyl)-ATP (BzATP), and bacterial lipopoly-
saccharide (LPS) were from Sigma (St. Louis, MO). NS398,
SC560, Butaprost, and Bromoenol lactone (BEL) were from
Cayman Chemicals, Ann Arbor, MI). Arachidonyl trifluoromethyl
ketone (AACOCF3) was from Biomol (Plymouth Meeting, PA).
A438079 was from Tocris (Ellisville, MO). Neurobasal medium
and B27 supplement were from Invitrogen (Carlsbad, CA). Fetal
bovine serum and Penicillin/Streptomycin solution were from
Atlanta Biologicals (Lawrenceville, GA). All other cell culture
reagents were from MediaTech Inc. (Herndon, VA). All other
chemicals were purchased from Sigma.
Animals, surgical procedures, and drug treatments
All experimental procedures were approved by the Institutional
Animal Care and Use Committee of Weill Cornell Medical
College (Approval Number: 0710-678A). C57BL/6J mice were
obtained from Jackson Laboratories (Bar Harbor, ME). EP1
2/2,
nNOS
2/2, and P2X7
2/2 mice were supplied from in house
colonies [7,13,14,15]. Null mice were on a C57Bl6 background
and C57Bl6 mice were used as wild type controls. Male mice (age
2–3 months) were used for all experiments.
1. Determination of cortical lesion volumes after local
NMDA injections. As described in detail elsewhere [16], cortical
NMDA injections (20 nmol in 200 nl) were carried out in isoflurane
anesthetized mice (2% in oxygen) using a micropipette
stereotaxically placed in the parietal cortex at 1.5 mm posterior to
the bregma, 4.0 mm lateral and 0.8 mm below the dura. Lesion
volumes were determined after 24 hours in Nissl-stained coronal
brain sections using a computerized image analysis system [16,17].
Where indicated, animals received NS398 (20 mg/kg; i.p.) or
vehicle (200 ml 0.1 M Na2HPO4 pH 7.0; i.p.) 1 hour before and
1 hour after cortical NMDA injections. SC560 (5 mg/kg; i.p.) or
vehicle(100 ml 10%DMSO inphysiol. Saline;i.p.) was given 1 hour
before and 6 hours after cortical NMDA injections. Doses and
administration schedule were chosen based on the results of
previous studies [16,18]. The selectivity and specificity of SC560
and NS398 at the doses used was demonstrated previously [17,19].
Some animals were injected with 20 nmol NMDA together with
170 fmol Butaprost or vehicle (0.014% ethanol). This dose of
Butaprost has been shown to be neuroprotective in this model [16].
In some animals oxATP (300 nmol in 3 ml physiol. saline) or vehicle
(3 ml physiol. saline) was stereotaxically delivered to the right lateral
ventricle (0.5 mm posterior to the bregma, 1.0 mm lateral, 2.0 mm
below the dura) 30 minutes before NMDA injections. The dosage
was chosen to reflect the effective concentration of oxATP used for
in vitro experiments(1 mM). The specific competitiveP2X7receptor
antagonist A438079 (200 mmol/kg in physiol. saline; i.p.) or vehicle
(100 ml physiol. saline; i.p.) was given 1 hour before cortical NMDA
injections. This dosage has been shown to induce anti-nociceptive
behavior in a model of neurophatic pain in mice [20].
2. Measurment of cortical PGE2 levels after local NMDA
injections. Animals were treated with SC560 and/or NS398 or
respective vehicles as described above. Cortical NMDA injections
were carried out as described above. Some animals were i.c.v.
injected with oxATP or corresponding vehicle as described above.
Where indicated, the non-competitive NMDA receptor antagonist
MK-801 (3 mg/kg in physiol. saline; i.p.) or vehicle (175 ml
physiol. saline; i.p.) was administered 30 minutes before cortical
NMDA injections. At indicated time points animals were deeply
anesthetized with isoflurane, decapitated and brains removed. The
cortex at the site of injection (10–12 mg wet weight) was dissected
and frozen in liquid nitrogen. Care was taken to limit the time
for tissue harvesting to 45–55 seconds. Tissue extracts were pre-
pared, purified over C18 cartridge columns and ELISA was per-
formed according to manufacturer’s recommendations (Cayman
Chemicals).
Immunofluorescence staining and confocal microscopy
Brains were removed from animals transcardially perfused with
4% paraformaldehyde and post-fixed overnight in 4% parafor-
maldehyde containing 20% sucrose. Coronal sections were
collected on a cryostat. Injection needle tracks were visualized in
Nissl stained sections and adjacent sections were used for
immunofluorescence staining. The location of the cortical lesion
eight hours after NMDA injection was determined by the clearly
visible opacity of the lesioned area. Frozen sections were blocked
with serum and incubated with respective primary antibodies
directed against neuronal nuclear antigen (NeuN, clone A60,
mouse IgG1, Chemicon, Temecula, CA, 1:1000), glial fibrillary
acidic protein (GFAP, clone GA5, mouse IgG1, Sigma, 1:5000),
ionized calcium binding adaptor molecule 1 (Iba1, rabbit
polyconal, Wako, 1:500), COX-1 (goat polyclonal, sc-1754, Santa
Cruz Biotechnology, Santa Cruz, CA, 1:200), or COX-2 (goat
polyclonal, sc-1746, Santa Cruz Biotechnology, 1:100). Respective
secondary antibodies were incubated for 1 hour at room
temperature (donkey-anti-mouse IgG-FITC, donkey-anti-rabbit
IgG-FITC, donkey-anti-goat-Cy5; all at 1:200, Jackson Immunor-
esearch, West Grove, PA). Mounted sections were analyzed on a
SP5 confocal laser scanning microscope (Leica Microsystems,
Bannockburn, IL) using adequate excitation lines and emission
bands. No spectral overlap was observed between FITC and Cy5
acquisition channels. Data are presented as average orthographic
projections of 40–48 images obtained at 200 nm Z-axis resolution.
Cell cultures
Neuronal cultures were established from cortices of E17 C57/
Bl6J mouse embryos as described [7] and used between days 11–
13 in culture. We have previously shown that COX-2 is expressed
in neurons cultured under these conditions [7]. Purity of neuronal
cultures was estimated to be above 95% by immunofluorescent cell
staining using antibodies directed against NeuN and GFAP. Mixed
glia were cultured from neonatal C57/Bl6J mice and microglia
were prepared after 21 days in culture by limited trypsinization as
described elsewhere [21]. Microglia were used for experiments 2–3
days after trypsinization. In some experiments COX1
2/2
(Taconic; [22]) or P2X7
2/2 microglial cultures were used. Purity
of preparations was assessed by indirect immunofluorescence
staining using anti-F4/80 (microglial marker) and anti-GFAP
antibodies or by flow cytometry using a CD11b specific antibody.
Microglia constituted .97% of total cells. Neuron-microglia co-
cultures were obtained by seeding 5610
4 microglia isolated from
mixed glial cultures by shaking the cultures at 37uC [23] on top of
neurons cultured in 12well plates as described above. Co-cultures
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were repeated on cells derived from different isolations.
PGE2 measurements in neuronal and glial cultures
PGE2 released from cultured cells was measured in cell culture
supernatants. Cells were pre-treated with vehicle (DMSO at
0.033% final concentration) or inhibitors added directly to the
growth medium for 1 hour. Cells were then washed twice in warm
physiologic salt solution (PSS: NaCl 130, CaCl2 1.8, Glucose 20,
HEPES 10, and KHCO3 3 mM, pH 7.35) and incubated in PSS
containing inhibitors and/or agonists for 30 minutes after which
cell culture supernatants were collected. LPS treatments lasting
longer than 30 minutes were carried out in growth medium.
30 minutes before end of stimulation cells were washed twice and
incubated in PSS as described above. PGE2 ELISA was performed
according to manufacturer’s recommendations (Cayman Chemi-
cals).
Determination of microglial cyclooxygenases expression
Cultured microglia were stimulated with LPS (1 mg/ml) for
indicated times, washed in PBS and lysed in Laemmli buffer.
Western blotting was carried out essentially as described [24] by
probing membranes with COX-1 or COX-2 specific antibodies.
Equal loading was assured by probing membranes for b-actin.
Extracellular ATP measurements in neuronal cultures
Neurons were exposed to NMDA (1 mM) added directly to the
culture medium. Supernatant was carefully removed to avoid cell
aspiration and centrifuged (5000 g, 3 minutes at 4uC) to eliminate
any cellular components. ATP in the medium was measured in
duplicate samples by the luciferin/luciferase reaction in a plate
luminometer (Berthold, Oak Ridge, TN) as suggested by the
manufacturer (Promega, Madison, WI). All samples were
processed within 30 minutes after harvest.
Data analysis
Data are expressed as means 6 SEM. Two-group comparisons
were analyzed by the two-tailed t test for dependent or
independent samples, as appropriate. Multiple comparisons were
evaluated by ANOVA and Tukey’s tests. Statistical significance
was considered for p,0.05.
Results
Time-course of PGE2 production after cortical NMDA
injection
First, we investigated the time course of PGE2 production in
mice after cortical NMDA injections. Basal levels of PGE2
(2.960.5 ng/g tissue; n=5) were comparable to those previously
described [7]. NMDA injection elicited a biphasic increase in
PGE2, characterized by a rapid increase at 10 min, followed by a
return to baseline between 30 min and 2 hrs, and a slower
increase at 8 hrs (Fig. 1A). The rapid PGE2 reduction between 10
and 30 min after NMDA is consistent with the rate of clearance of
prostanoids in the mouse cortex [25]. Basal levels of PGE2 were
markedly attenuated in mice treated with the COX-1 inhibitor
SC560 (28563% compared to vehicle treated animals), while the
COX-2 inhibitor NS398 had no effect on basal PGE2 (Fig. 1A).
The early peak of PGE2 production was virtually abolished by
SC560 (29662% compared to vehicle), but was not affected by
NS398 (Fig. 1A). In contrast, the late increase in PGE2 was
attenuated by both SC560 and NS398, although NS398 was more
effective at 8 (258610% compared to vehicle) and 24 hours
(27065% compared to vehicle) (Fig. 1A). Co-administration of
both COX-1 and COX-2 inhibitors blocked NMDA-induced
PGE2 production completely at all time points (p,0.05 from
vehicle) (Fig. 1A). To rule out the possibility that the PGE2
production seen at the early time point was caused by the trauma
of the micropipette insertion and not by NMDA receptor
activation, we performed the vehicle and NMDA injections with
or without the NMDA receptor antagonist MK-801. Treatment
with MK-801 markedly attenuated PGE2 levels 10 min after
NMDA injection (Fig. 1B). Vehicle injection caused a significant
increase in PGE2 that was however not suppressed by MK-801,
but was significantly lower than that observed after NMDA
injection (Fig. 1B). This data suggest that trauma contributes
moderately to the early PGE2 increase after cortical NMDA
injections by a NMDA receptor-independent mechanism. In
summary, COX-1 contributes to basal PGE2 production and to
the early PGE2 peak after cortical NMDA injections, while both
enzymes contribute to PGE2 synthesis at later time points.
Figure 1. COX-1 and COX-2 contribute to PGE2 production
after cortical NMDA injections. (A) Time course of PGE2 production
after cortical NMDA injections. NMDA (20 nmol) was injected stereo-
tactically into the parietal cortex. Were indicated animals received
NS398 and/or SC560 as described in Methods. Vehicle consisted of
100 ml DMSO:Saline (1:9) administered i.p. PGE2 tissue levels were
measured by ELISA (n=5/group, * p,0.05 from vehicle treated group
at the same time point, # p,0.05 from sham receiving the same
systemic drug treatment). (B) Animals were treated with MK-801 (MK,
3 mg/kg; i.p.) or vehicle (175 ml 0.9% saline; i.p.) 30 minutes before
cortical injections of NMDA (20 nmol in 200 nl) or vehicle (200 nl of
0.1 M phosphate buffer, pH 7.4). Tissue was collected 10 minutes after
cortical injection. PGE2 tissue levels were measured by ELISA (n=4/
group, * p,0.05 from sham, # p,0.05 from NMDA+Sal).
doi:10.1371/journal.pone.0025916.g001
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COX-2 inhibition, EP1 receptor deletion, or EP2 receptor
activation, but not nNOS deletion
Results from our laboratory have provided evidence that
COX-2, but not COX-1, is involved in the cortical lesions
produced by NMDA [11,17]. We have also shown that PGE2,
and not other COX-2 reaction products mediate the neurotoxic
effect [16]. Because COX-1 activity contributes substantially to
NMDA-induced PGE2 production (Fig. 1A), we addressed the
relative contribution of COX-1 and COX-2 to the development
of excitotoxic lesions by pharmacologic inhibition of one or both
enzymes. Consistent with previous findings, the lesion produced
by NMDA was attenuated in mice treated with NS398, but not
SC560 (Fig. 2A). However, treatment with both inhibitors
abolished the protective effect obtained with COX-2 inhibition
alone (Fig. 2A). EP1 receptors are the downstream effector of
COX-2 mediated neurotoxicity [6,7]. Therefore, we used EP1
2/2
mice to investigate the role of COX-1 in the protective effect of
EP1 deletion. As previously reported, lesion size was reduced in
EP1
2/2 mice (23365% compared to wild type animals,
Fig. 2B). However, when EP1
2/2 mice were treated with
SC560 the lesion volume increased and was comparable to that
observed in wild type mice (Fig. 2B). Because PGE2 can have
neuroprotective effects through activation of EP2 receptors [8],
we also investigated the role of COX-1 in the neuroprotection
induced by EP2 receptor activation. The EP2 receptor agonist
butaprost reduced NMDA-induced lesions (22764% compared
to vehicle control), but the protection was abolished in mice
treated with SC560 (Fig. 2C). However, SC560 failed to reverse
the protection observed in nNOS2/2 mice (Fig. 2D). There-
fore, COX-1 activity is required for the protective effect exerted
by COX-2 inhibition, EP1 receptor deletion and EP2 receptor
activation, but might not play a role in other excitotoxic
pathways.
COX-1 and COX-2 are expressed in different cell types in
the mouse cortex
The observation of a distinct temporal profile of PGE2
synthesis by COX-1 and COX-2, let us to ask whether
expression of the two COX isoforms occurs in different cell
types. Therefore, we examined the cellular localization of COX-
1 and COX-2 immunoreactivity (IR) in the mouse cortex by
double labeling with neuronal, astrocytic, and microglial
markers. At 10 minutes after cortical NMDA injection, COX-2
IR was localized primarily in neurons, exhibiting the well-
described perinuclear staining pattern [26] (Fig. 3). Because the
neuronal marker NeuN is only expressed in the nucleus and
perikaryon we could not examine localization of COX-2 in axons
or dendrites. Consistent with previous findings [27], not all
neurons showed detectable COX-2 IR. Occasionally, COX-2 IR
could be seen in microglia, in which a condensed perinuclear
staining pattern was observed (Fig. 3). COX-2 IR was not
observed in GFAP-positive astrocytes (Fig. 3). At 8 hours after
NMDA, COX-2 IR was markedly increased in neurons of the
perilesional cortex. However, COX-2 IR was lost in the lesioned
area, together with NeuN IR, most likely reflecting neuronal cell
loss. As previously reported [28,29] COX-1 IR was primarily
observed in Iba1 positive microglia, wherein it showed a diffuse
cytoplasmic staining pattern. Most identified microglia showed
COX-1 IR. Eight hours after NMDA injection COX-1 IR was
still confined to Iba1 positive cells (Fig. 3).
ATP stimulates COX-1 dependent PGE2 production in
microglia in vitro
Having established that COX-1 expression is limited to microglia
we investigated circumstances that would induce PGE2 release from
these cells in vitro. Cultured mouse primary cortical microglia were
treated with NMDA (1 mM), glutamate (300 mM), LPS (1 mg/ml),
Figure 2. COX-1 inhibition reverses protection obtained by
COX-2 inhibition, EP1 receptor deletion, and EP2 receptor
activation. (A) Cortical lesion volumes were determined from thionine
stained serial brain sections 24 hours after NMDA injection. Where
indicated, animals received NS398 and/or SC560 as described in
Methods. Vehicle consisted of 100 ml DMSO:Saline (1:9) administered
i.p. (n=6–9/group, * p,0.05). (B) NMDA lesion volumes in EP1
2/2 mice
systemically treated with vehicle (as in A) or SC560 (n=5/group,
*p ,0.05 from vehicle). (C) Mice received the EP2 receptor agonist
Butaprost (170 fmol) together with NMDA resulting in reduced lesion
volumes. Lesions are enlarged in mice receiving SC560 (vehicle as in A;
n=9/group; * p,0.05 from vehicle). (D) Reduced lesion in nNOS
2/2
mice is not reversed by SC560 (n=6/group; n.s.=non significant).
doi:10.1371/journal.pone.0025916.g002
Cyclooxygenase-1 in Excitotoxicity
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25916orATP(1 mM)for30 minutes and PGE2 levels wereassessed inthe
supernatant. Only ATP induced robust PGE2 production (Fig. 4A).
In contrast, PGE2 production was unchanged in neurons treated
with ATP or the other agonists studied (Fig. 4B). LPS has been
shown to induce PGE2 production in microglia [30,31], but we
failed to detect PGE2 30 minutes after LPS treatment. Therefore,
we asked whether LPS could induce PGE2 release at later time
points. LPS strongly induced PGE2 release after 8 and 24 hours
exposure (Fig. 4C). This increase was mirrored by up-regulation of
COX-2 protein that was barely detectible in non-stimulated
microglia, while COX-1 was constitutively expressed and protein
levels were not altered by LPS treatment (Fig. 4D).
P2X7 receptors are essential for ATP induced microglial
PGE2 production in vitro
Next we examined the signaling cascade that leads to ATP-
dependent PGE2 production in microglia. The fact that PGE2
production was observed when cells were stimulated with high
(1 mM), but not low (10–100 mM; data not shown), concentrations
of ATP suggested that microglial purinergic receptors of the P2X7
subtype may be involved [32]. Consistent with this hypothesis the
preferential P2X7 receptor agonist BzATP was able to induce the
same level of PGE2 production at a 10-fold lower concentration
than ATP while the irreversible P2X7 receptor antagonist oxATP
completely blocked ATP induced PGE2 release (Fig. 5A). SC560
blocked ATP-induced PGE2 production, attesting to the involve-
ment of COX-1 in the process. The Ca
2+-dependent enzyme
phospholipase A2 (PLA2) releases arachidonic acid from cell
membrane phospholipids, which, in turn, serves as substrate for
COX-dependent PGH2 synthesis [33]. Because P2X7 receptors
are ATP gated ion channels, we examined whether Ca
2+ influx
and PLA2 activation are required for the COX-1-dependent
PGE2 production induced by ATP. We found that PGE2
production is virtually abolished by removal of extracellular
Figure 3. COX-1 and COX-2 expression in the mouse cerebral cortex. Double immunofluorescence labeling of COX enzymes together with
Iba1 (microglia), GFAP (astrocytes), or NeuN (neurons) marker proteins 10 minutes or 8 hours after cortical NMDA injections. COX-1 IR co-localizes
with Iba1, but not with NeuN or GFAP. COX-2 IR co-localizes with NeuN, but not with GFAP. There is some discrete COX-2 IR associated with Iba1
positive cells. The dotted line marks the lesion border in 8 hour samples. Lesion areas also show reduced NeuN and COX-2 IR.
doi:10.1371/journal.pone.0025916.g003
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2+ (Fig. 5A). Furthermore, the non-selective PLA2 inhibitor
AACOCF3 blocked PGE2 production, while the Ca
2+-indepen-
dent PLA2 inhibitor BEL had no effect (Fig. 5A). Accordingly,
ATP induced PGE2 release was abolished in microglia derived
from COX-1
2/2 or P2X7
2/2 animals, while PGE2 release after
16 hours LPS stimulation, which is mainly COX-2 dependent
(Fig. 4C and 4D), was not affected (Fig. 5B). Collectively these
observations indicate that ATP induces PGE2 production through
Ca
2+ entry via P2X7 receptors and subsequent cPLA2 and COX-
1 activation.
NMDA elicits ATP release from cultured cortical neurons
and induces PGE2 production in neuron-microglia
co-cultures in a P2X7 receptor dependent manner
Our in vivo findings indicate that the COX-1-dependent early
PGE2 production is mediated by NMDA receptor activation
(Fig. 1B), while our in vitro studies revealed a central role for
microglial P2X7 receptors in COX-1-dependent PGE2 production
after ATP exposure. Therefore, we hypothesized that neurons
might release extracellular ATP after NMDA receptor activation
that in turn would activate P2X7 receptors on microglia resulting
in COX-1 activation and PG production. To test this hypothesis
we treated cortical neuron cultures with NMDA (1 mM) and
determined ATP in the culture medium at different time points
after NMDA addition. NMDA triggered ATP release at 2 and
5 minutes (Fig. 6A). No significant ATP increase was observed at
later time points.
Asserting the role of neuronal ATP in driving microglial PG
production, we found that NMDA induced PGE2 production in
neuron-microglia co-cultures, but not in pure neuronal or
microglial sister cultures (Fig. 6B). When wild type neurons were
co-cultured with P2X7
2/2 microglia no PGE2 production was
observed after NMDA or ATP treatment (Fig. 6C). These findings
support the conclusion that neuronal ATP release after NMDA
stimulation triggers microglial PGE2 production through P2X7
receptor activation.
P2X7 receptors contribute to NMDA induced PGE2
production in vivo and have an essential role in the
neuroprotection conferred by the COX-2 inhibition
Having established that P2X7 receptors are upstream of COX-
1 mediated PGE2 production in microglia and that ATP released
from neurons after NMDA receptor activation might be a trigger
for their activation, we tested the hypothesis that P2X7 receptors
also mediate COX-1 dependent PGE2 production after NMDA
challenge in vivo. Because early PGE2 release in this excitotoxic
model is solely COX-1 dependent (Fig. 1), we examined PGE2
production 10 minutes after NMDA injection in mice that have
been pretreated with the P2X7 receptor blocker oxATP. PGE2
levels were significantly decreased in animals pretreated with
oxATP when compared to animals receiving vehicle alone
(Fig. 7A). Furthermore, similar to the effects seen after COX-1
inhibition, pre-treatment with oxATP or with the selective P2X7
receptor antagonist A438079 reversed the protection offered by
NS398 treatment, confirming that P2X7 receptors are essential for
COX-1 mediated prostanoid production after cortical NMDA
injections (Fig. 7B and 7C).
Discussion
Purinergic receptors play a central role in shaping the microglial
response to physiologic and pathologic environmental cues [34].
Here we identified P2X7 receptors as regulators of COX-1
dependent PGE2 production in microglia and determined the
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Figure 4. ATP is an immediate inducer of microglial PGE2 production. Cultured cortical microglia (A) or neurons (B) were exposed to NMDA
(1 mM), glutamate (Glu; 300 mM), LPS (1 mg/ml) or ATP (1 mM) for 30 minutes. PGE2 levels in supernatants were determined by ELISA (n=6/group
derived from 3 independent experiments, * p,0.05). (C) Microglia were exposed to LPS (1 mg/ml) for indicated time points and PGE2 was assayed in
the supernatant by ELISA (n=6/group derived from 3 independent experiments). (D) Microglial COX-1 and COX-2 expression levels after LPS (1 mg/
ml) treatment were determined by western blot analysis. Blots are representative for four independent experiments.
doi:10.1371/journal.pone.0025916.g004
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excitotoxic cortical brain lesions.
We show that ATP is a strong inducer of COX-1 dependent
PGE2 production in primary microglial cultures. The fact that
microglial PGE2 release occurred within 30 minutes after ATP
exposure makes it likely that the release is dependent on the
activation of a constitutive synthetic machinery, rather than on
transcriptional induction of such components. COX-1 is the
predominant cyclooxygenase isoform expressed in resting microg-
lia in vivo (Fig. 3) and in vitro (Fig. 4D). In contrast little constitutive
COX-2 protein is expressed and up-regulation requires prolonged
exposure to a pro-inflammatory stimulus such as LPS (Fig. 4D).
Microglia express several purinergic receptors, including members
of the G-protein coupled P2Y family and ionotropic P2X
receptors [34]. Here we present evidence that P2X7 receptors
are instrumental for ATP induced PGE2 release in microglia. First,
relatively high (mM) ATP concentrations are needed to elicit
PGE2 production. Low potency of ATP is a signature of the P2X7
receptor, while P2Y and other P2X receptors are activated at 10
fold lower concentration [35]. Second, exposure of microglia to
100 mM BzATP is as effective as 1 mM ATP in releasing PGE2.
Although capable of binding other P2X receptors, BzATP shows
high potency only for the P2X1 and P2X7 receptor [36]. Third,
oxATP, which is an irreversible inhibitor with good specificity for
the P2X7 receptor [37], efficiently blocked microglial PGE2
production. Finally, the ATP response was blunted in P2X7
2/2
microglia.
Our data suggest that cPLA2 is activated in response to P2X7
receptor activation. Thus, PGE2 production in our model is
dependent on extracellular Ca
2+ and is inhibited by the non-
selective PLA2 blocker AACOCF3. The observation that BEL, an
inhibitor of Ca
2+-independent cPLA2c, does not attenuate PGE2
production indicates the involvement of Ca
2+ dependent cPLA2a
activity.
We also demonstrated that NMDA receptor activation results in
rapid ATP release from cortical neurons. ATP may be secreted by
neuronal activity from pre-synaptic vesicles where ATP concen-
trations can be as high as 150 mM [38]. Indeed, glutamate-
induced ATP release has been reported in Xenopus spinal neurons
[39]. Alternatively, ATP can be released from neurons as a result
of injury when cytoplasmic ATP, which is estimated to be in the
range of 10–100 mM, leaks to the extracellular space. Consistent
with this scenario, focal cerebral ischemia in rats results in early
increases in extracellular ATP [40]. It is therefore conceivable that
mM concentrations of ATP may be reached in the vicinity of
microglia after exposure to excitotoxic levels of NMDA, resulting
in P2X7 receptor activation. This interpretation is supported by
our findings that NMDA elicits PGE2 production in neuron-
Figure 5. P2X7 receptors mediate ATP but not LPS induced PGE2 release in microglial cultures. (A) Microglia were treated with ATP
(1 mM) or the P2X7 receptor agonist BzATP (100 mM) alone or together with the P2X7 receptor inhibitor oxATP (1 mM), the PLA2 inhibitor AACOCF3
(20 mM), the COX-1 inhibitor SC560 (1 mM), or the Ca
2+-independent PLA2 inhibitor BEL (10 mM). Some experiments were conducted in Ca
2+-free
extracellular solution (Ca-free). PGE2 levels in supernatants were determined by ELISA (n=8–12/group derived from 4–6 independent experiments,
*p ,0.05 from all others except ATP, BzATP, and BEL+ATP groups). (B) Microglia derived from wild type, COX1
2/2, or P2X7
2/2 animals were
stimulated with ATP (1 mM) for 30 minutes or LPS (1 mg/ml) for 16 hours. Vehicle consisted of 5 ml PBS. PGE2 levels in supernatants were determined
by ELISA (n=6/group derived from 3 independent experiments, * p,0.05 from other groups with same treatment).
doi:10.1371/journal.pone.0025916.g005
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cultures, and that this production is dependent on microglial P2X7
receptors.
We assessed the relative contribution of COX-1 and COX-2 in
NMDA induced PGE2 production and tissue damage in the
mouse cortex. As previously reported [11,17], pharmacological
inhibition of COX-2 reduced lesion volumes, while COX-1
inhibition had no effect. However, inhibition of both isoforms
abolished the protection observed with COX-2 inhibition. Thus,
COX-1-derived reaction products do not reduce NMDA-induced
brain damage, but are able to protect the brain if COX-2 is
inhibited. Similarly, COX-1 inhibition abolished the protection
observed in mice lacking EP1 receptors, and the protective effect
induced by EP2 receptor activation. COX-1 was observed
exclusively in microglia, and was activated by purinergic signaling
leading to cPLA2 activation. Experiments in neuron-microglia co-
cultures indicated that neurons are the source of ATP driving
purinergic signaling and COX-1 activity. The data provide new
evidence for a neuroprotective role of microglial COX-1 in the
setting of excitotoxic brain injury.
The cortical PGE2 production induced by excitotoxicity follows
a biphasic temporal profile. While COX-1 accounts for the early
PGE2 release, which peaks 10 minutes after NMDA injection,
both COX-1 and COX-2 contribute to the late PGE2 production
that is maximal at 8 hours after the NMDA challenge. Co-
administration of COX-1 and COX-2 inhibitors lowered PGE2
below baseline levels for at least 24 hrs, indicating that the
concentrations used were sufficient to block both enzymes
throughout the experiment. Interestingly, the early PGE2
production was only partially dependent on NMDA receptor
activation, because MK-801 did not reduce PGE2 down to
baseline levels. Indeed, vehicle injection was sufficient to trigger
PGE2 release, which, in contrast to NMDA, could not be blocked
by MK-801. It is therefore likely that the NMDA-independent
component of the early PGE2 production is related to the trauma
caused by insertion of the micropipette. Similar cortical injuries
have been shown to cause purine release from damaged cells [41],
and it is tempting to speculate that these purines activate COX-1-
dependent PGE2 production through microglial purinergic
receptors.
The mechanisms of the protective effect exerted by COX-1 in
the setting of COX-2 inhibition have not been elucidated. One
possibility is that COX-1-released PGE2 preferentially acts on
cytoprotective Gs-coupled EP receptors, such as EP2 or EP4
[8,42,43]. Our data do not rule out this possibility, although the
reversal of EP2 receptor mediated neuroprotection by COX-1
inhibition would suggest that the EP2 receptor is not the target for
COX-1 derived PGE2. The role of EP4 receptors in this paradigm
remains to be explored. Another possibility is that, in addition to
PGE2, other prostanoids released by microglia play a role in the
protection. Thus, microglial COX-1 could be linked to PG
synthases distinct from those associated with neuronal COX-2,
resulting in synthesis of different prostanoids in the two cell types.
It has become clear that several prostanoid receptors can initiate
neuroprotective signaling [44]. In this respect it is interesting that
mice deficient in the hematopoietic PGD2 synthase isoform, which
in brain is exclusively expressed in microglia and perivascular
macrophages, are more susceptible to hypoxic-ischemic damage
[45]. This effect is coupled to activation of G-coupled DP1
receptors which are neuroprotective [45,46].
Alternatively, COX-2 and COX-1 derived prostanoids might
have different cellular targets. We have previously established that
EP1 receptors mediate COX-2 neurotoxicity [7]. Because COX-1
inhibition reverts the protected phenotype in EP1
2/2 mice, it
could be argued that COX-1-derived prostanoids counteract a
pathogenic mechanism that is not directly linked to neuronal
COX-2. This assumption is also supported by the fact that EP2
Figure 6. NMDA triggers neuronal ATP release and induces
PGE2 production in neuron-microglia co-cultures. (A) Neurons
were exposed to NMDA (1 mM) and extracellular ATP (ecATP) levels
were determined in the supernatant (n=8/group derived from 4
independent experiments, * p,0.05 from 0). (B) Co-cultured microglia/
neurons or separately cultured microglial and neuronal sister cultures
were exposed to ATP (1 mM) or NMDA (1 mM) for 30 minutes. Vehicle
consisted of 5 ml PBS. PGE2 was determined in supernatants (n=12/
group derived from 6 independent experiments, * p,0.05 from vehicle
of the respective group). (C) wt neurons were co-cultured with wt or
P2X7
2/2 microglia and stimulated as described in B (n=6/group
derived from 3 independent experiments, * p,0.05 from vehicle of the
respective group).
doi:10.1371/journal.pone.0025916.g006
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intracellular cAMP levels [8], could not override the deleterious
effect of COX-1 inhibition (Fig. 2). Although in the excitotoxic
model used in the present study neuronal cell fate is mainly
dependent on intrinsic neuronal mechanisms, i.e. energy deple-
tion, intracellular Ca
2+ overload, oxidative stress, protease
activation, and mitochondrial dysfunction [47], involvement of
microglia has also been suggested [48,49]. Because PGD2 is the
precursor for the peroxisome proliferators activator receptor-c
(PPARc) ligand 15-Deoxy-
D12,14-PGJ2, it is possible that COX-1
might be linked to PPARc activation which has been shown to
mitigate microglial pro-inflammatory response in a variety of
models [50]. Thus COX-1 might be part of an autocrine loop to
limit microglia activation after excitotoxic brain lesions. However,
the protective effect of COX-1 derived prostanoids might be
limited to excitotoxic neuronal cell death. For example, in contrast
to our findings, COX-1 contributed to neuronal cell death after
neuroinflammation triggered by intracerebroventricular LPS
injection [51]. Interestingly, COX-1 inhibition did not reverse
the protected phenotype of nNOS
2/2 animals. Thus, the
neuroprotective contribution of COX-1 is likely to be pathway
specific, and might be confined to the cerebral prostanoid system.
In addition, we cannot exclude the involvement of lipid
mediators not directly produced by the COX system. Apart from
COX, arachidonic acid can be metabolized by lipoxygenases to
form leukotrienes and lipoxins and the cytochrome P450 pathway
to form epoxyeicosatrienoic acids (EETs) and hydroxyeicosate-
traenoic acids (HETEs) [52]. Blocking COX could therefore shunt
arachidonic acid released after P2X7 receptor activation to be
utilized by these pathways. Evidence suggests that several
lipoxygenase and P450 epoxygenase metabolites are neurotoxic
[53]. It is therefore conceivable that COX-1 inhibition could
increase lipoxygenase or cytochrome P450-derived neurotoxic
lipid mediators leading to a reversal of the neuroprotection
granted by COX-2 inhibition. It is however not clear why these
neurotoxins would be only relevant when COX-2 is inhibited and
not be neurotoxic in naı ¨ve animals or in nNOS
2/2 mice.
Finally we show that P2X7 receptors are pivotal for COX-1
activation after cortical NMDA injections in vivo. Animals
pretreated with the P2X7 receptor blocker oxATP showed
reduced early PGE2 production after cortical NMDA injection,
indicating that P2X7 receptors are activators of COX-1 mediated
PGE2 production in the setting of excitotoxic brain lesions. As
expected, we found that P2X7 receptor inhibition by oxATP or
the competitive antagonist A438079, similar to COX-1 inhibition,
reversed the protective effect afforded by the COX-2 inhibitor
NS398. This data further confirm that NMDA induced COX-1
activity is dependent on purinergic signaling through the P2X7
receptor.
In summary, we have provided evidence that COX-1 is solely
responsible for the early increase in PGE2 induced by cortical
injection of NMDA, and that COX-1 activity contributes to the
protective effect exerted by COX-2 inhibition, EP1 receptor
deletion, or EP2 receptor activation. In the cortex of naı ¨ve
animals, COX-1 is localized to microglia, whereas COX-2 is
present mainly in neurons. Microglial COX-1 coupled to PGE2
synthases is able to synthesize PGE2 in response to extracellular
ATP, probably released by an effect of NMDA on neurons rather
than microglia. COX-1 catalytic activity is increased as a result of
cPLA2a activation following Ca
2+ influx through the P2X7
receptor. These findings, collectively, suggest that neuronal release
of ATP following NMDA stimulation leads to activation of COX-
1 in microglia. Although the mechanisms by which COX-1-
derived prostanoids influence lesion outcome remain to be
defined, the data indicate that COX-1 in microglia is endowed
with a powerful neuroprotective potential, which could be
beneficial in the treatment of neurological diseases associated
with excitotoxicity.
Figure 7. In vivo inhibition of P2X7 receptors blocks NMDA induced PGE2 production and reverts the protective effect of NS398. (A)
Animals were injected i.c.v. with saline (ve; 3 ml) or the P2X7 receptor blocker oxATP (300 nmol in 3 ml). Thirty minutes later NMDA was delivered
stereotaxically to the parietal cortex. Brain tissue was collected 10 minutes after end of NMDA injection and PGE2 tissue levels were determined
(n=5/group; * p,0.05 from NMDA+ve). (B) Animals were treated as in A and both groups received NS398 (20 mg/kg i.p.). Lesion volumes were
determined 24 hours after NMDA injections (n=5/group; * p,0.05 from NMDA+ve). Note the slightly increased lesion volumes in NS398+ve treated
as compared to animals presented in Fig. 2A and 7C, a fact that could be related to surgical procedures associated with i.c.v. injections. (C) Animals
received NS398 (20 mg/kg i.p.) together with A438079 (200 mmol/kg in physiol. saline; i.p.) or vehicle (100 ml physiol. saline; i.p.). Lesion volumes were
determined 24 hours after NMDA injections (n=4/group; * p,0.05 from NMDA+ve).
doi:10.1371/journal.pone.0025916.g007
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